Liver transplantation for alpha-1-antitrypsin deficiency in children
Author(s) -
Andreas Prachalias,
Mohamed Kalife,
Ruggiero Francavilla,
Paolo Muiesan,
Anil Dhawan,
Alastair Baker,
Dino Hadzic,
Giorgina Mieli-Vergani,
Mohamed Rela,
N Heaton
Publication year - 2000
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1007/s001470050688
Subject(s) - medicine , alpha 1 antitrypsin deficiency , hepatosplenomegaly , liver transplantation , liver disease , pediatrics , jaundice , transplantation , population , disease , gastroenterology , environmental health
Alpha-1-antitrypsin (a1-AT) deficiency is an inborn error of metabolism, which can cause liver disease. The condition is one of the most common genetic disorders in the Caucasian population. Here we review our experience with 21 children suffering from end-stage liver disease due to a1-AT deficiency. All children are PIZZ homozygotes. Nineteen of them initially presented with neonatal jaundice and two with hepatosplenomegaly in childhood. Twenty-five liver transplantations were performed. All children are currently alive at a median followup of 40 months. Liver replacement provides the only definite treatment for children with end-stage liver disease associated with a1-AT deficiency. Excellent results can be achieved by reducing waiting time for transplantation and by early referral to a liver transplant centre.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom